These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35871401)

  • 1. SARS-CoV-2 infection in severe asthma is associated with worsening of COVID-19 through respiratory NLRP3 inflammasome activation.
    Jeong JS; Choi JY; Kim JS; Park SO; Kim W; Yoon YG; Park HJ; Park KH; Kim DH; Kim JM; Koh GY; Eo SK; Lee YC
    Allergy; 2023 Jan; 78(1):287-290. PubMed ID: 35871401
    [No Abstract]   [Full Text] [Related]  

  • 2. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
    Zhao N; Di B; Xu LL
    Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS.
    Nabavi SF; Sahebnasagh A; Shahbazi A; Nabavi SM; Azimi S; Kashani MK; Habtemariam S; Rahmani M; Badiee M; Hashemi J; Saghafi F; Amini K; Azimi M; Rezabakhsh A
    Curr Med Chem; 2023; 30(12):1406-1419. PubMed ID: 36065926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in the relationship between NLRP3 inflammasome and lung injury in COVID-19].
    Ren Z; Che P; Li Z; Mo M; Zhang S; Zhang Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Sep; 37(9):844-850. PubMed ID: 34533131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.
    Yong YY; Zhang L; Hu YJ; Wu JM; Yan L; Pan YR; Tang Y; Yu L; Law BY; Yu CL; Zhou J; Li M; Qin DL; Zhou XG; Wu AG
    Clin Immunol; 2022 Nov; 244():109093. PubMed ID: 35944881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinated regulation of interferon and inflammasome signaling pathways by SARS-CoV-2 proteins.
    Kim NE; Song YJ
    J Microbiol; 2022 Mar; 60(3):300-307. PubMed ID: 35089584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications.
    Potere N; Del Buono MG; Caricchio R; Cremer PC; Vecchié A; Porreca E; Dalla Gasperina D; Dentali F; Abbate A; Bonaventura A
    EBioMedicine; 2022 Nov; 85():104299. PubMed ID: 36209522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity.
    Amin S; Aktar S; Rahman MM; Chowdhury MMH
    Microbes Infect; 2022 Feb; 24(1):104913. PubMed ID: 34838941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection.
    de Almeida L; da Silva ALN; Rodrigues TS; Oliveira S; Ishimoto AY; Seribelli AA; Becerra A; Andrade WA; Ataide MA; Caetano CCS; de Sá KSG; Pelisson N; Martins RB; de Paula Souza J; Arruda E; Batah SS; Castro R; Frantz FG; Cunha FQ; Cunha TM; Fabro AT; Cunha LD; Louzada-Junior P; de Oliveira RDR; Zamboni DS
    Sci Adv; 2022 Sep; 8(37):eabo5400. PubMed ID: 36103544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein.
    Yalcinkaya M; Liu W; Islam MN; Kotini AG; Gusarova GA; Fidler TP; Papapetrou EP; Bhattacharya J; Wang N; Tall AR
    Sci Rep; 2021 Dec; 11(1):24432. PubMed ID: 34952919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting NLRP3 inflammasome in an animal model for Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Sergi CM; Chiu B
    J Med Virol; 2021 Feb; 93(2):669-670. PubMed ID: 32841451
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of NLRP3 inflammasome in COVID-19 and periodontitis: Possible protective effect of melatonin.
    Şehirli AÖ; Aksoy U; Koca-Ünsal RB; Sayıner S
    Med Hypotheses; 2021 Jun; 151():110588. PubMed ID: 33848919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the NLRP3 Inflammasome in Severe COVID-19.
    Freeman TL; Swartz TH
    Front Immunol; 2020; 11():1518. PubMed ID: 32655582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation.
    Pan P; Shen M; Yu Z; Ge W; Chen K; Tian M; Xiao F; Wang Z; Wang J; Jia Y; Wang W; Wan P; Zhang J; Chen W; Lei Z; Chen X; Luo Z; Zhang Q; Xu M; Li G; Li Y; Wu J
    Nat Commun; 2021 Aug; 12(1):4664. PubMed ID: 34341353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulatory Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in Endothelial Cells.
    Sur S; Steele R; Isbell TS; Ray R; Ray RB
    mBio; 2022 Jun; 13(3):e0095122. PubMed ID: 35587188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro.
    Milara J; Martínez-Expósito F; Montero P; Roger I; Bayarri MA; Ribera P; Oishi-Konari MN; Alba-García JR; Zapater E; Cortijo J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.
    Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Alruwaili M; AlRuwaili R; Albogami SM; Alorabi M; Saad HM; Simal-Gandara J
    Inflammopharmacology; 2023 Feb; 31(1):1-7. PubMed ID: 36418600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLRP3 inflammasome: A joint, potential therapeutic target in management of COVID-19 and fertility problems.
    Bazrafkan M; Hosseini E; Nazari M; Amorim CA; Sadeghi MR
    J Reprod Immunol; 2021 Nov; 148():103427. PubMed ID: 34563758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent.
    Declercq J; De Leeuw E; Lambrecht BN
    Cytokine; 2022 Sep; 157():155934. PubMed ID: 35709568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
    Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
    Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.